ColoCare Study - Colorectal Cancer Cohort

Description

ColoCare is an international prospective cohort study of stage I-IV colorectal cancer patients (ICD-10 C18-C20).

Conditions

Colorectal Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

ColoCare is an international prospective cohort study of stage I-IV colorectal cancer patients (ICD-10 C18-C20).

ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis

ColoCare Study - Colorectal Cancer Cohort

Condition
Colorectal Cancer
Intervention / Treatment

-

Contacts and Locations

Los Angeles

Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048

Tampa

Lee H. Moffitt Cancer Center, Tampa, Florida, United States, 12902

Saint Louis

Washington University School of Medicine, Saint Louis, Missouri, United States, 63112

Knoxville

University of Tennessee, Knoxville, Tennessee, United States, 37996

Salt Lake City

Huntsman Cancer Institute, Salt Lake City, Utah, United States, 84112

Seattle

FHCRC, Seattle, Washington, United States, 98109-1024

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age 18-89 years; for patients recruited after 09/01/2021 the age range is 18-69 years. Recruitment of patients 70 years and older was maintained for specific sub-studies and re-initiated for specific R01 grant funding in \~06/2024
  • 2. Men and women
  • 3. Newly-diagnosed colon or rectal cancer (stages I-IV); CRC in treatment (FHCRC and HCI)
  • 4. English (FHCRC, Moffitt, HCI, Cedars-Sinai, WashU St. Louis) or German (University Hospital Heidelberg)-speaking;
  • 5. mentally/physically able to consent and participate.
  • * if one of the above in not fulfilled
  • * insufficient language or consent capacity

Ages Eligible for Study

18 Years to 89 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Utah,

Cornelia M Ulrich, MS, PhD, PRINCIPAL_INVESTIGATOR, Huntsman Cancer Institute

William Grady, MD, PhD, PRINCIPAL_INVESTIGATOR, Fred Hutchinson Cancer Center

Christopher Li, MD, PRINCIPAL_INVESTIGATOR, Fred Hutchinson Cancer Center

Doratha Byrd, PhD, PRINCIPAL_INVESTIGATOR, Lee H. Moffitt Cancer Center

Jane Figueiredo, PhD, PRINCIPAL_INVESTIGATOR, Cedars-Sinai Medical Center

David Shibata, MD, PRINCIPAL_INVESTIGATOR, University of Tennesee

Adetunji T. Toriola, MD, PhD, PRINCIPAL_INVESTIGATOR, Washington University School of Medicine

Biljana Gigic, PhD, PRINCIPAL_INVESTIGATOR, Heidelberg University

Study Record Dates

2030-10